Medicus Pharma Ltd.
MDCXW
NASDAQ0.48
USD
+0.09
- -
Medicus Pharma Ltd.
MDCXW
(NASDAQ)
Recent
price
0.48
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Medicus Pharma Ltd. (NasdaqCM:MDCXW) is a clinical-stage pharmaceutical company focused on developing and commercializing novel treatments for oncology and infectious diseases. The company advances a pipeline of drug candidates, including its lead asset Iconic Therapeutics' ICON-1001, a novel immuno-oncology therapy targeting advanced solid tumors; proprietary antibiotics such as MRX-6038 and MRX-6039 for treating multidrug-resistant bacterial infections; and antiviral programs addressing unmet needs in virology. These offerings encompass small-molecule drugs, antibody-drug conjugates, and immunotherapy platforms designed for hospital and outpatient settings, with a primary emphasis on orphan indications and high-unmet-need patient populations in North America and Europe. Founded in 2023 and headquartered in Miami, Florida, Medicus Pharma operates through subsidiaries including Iconic Therapeutics, Inc., which provides expertise in antibody-targeted therapies; MRX Medical LLC, specializing in next-generation antibiotics; and Sentinel Health Solutions LLC, focused on data-driven drug development services. The company targets healthcare providers, academic institutions, and biopharma partners across the United States, with expanding clinical trial footprints in Europe and Asia. In the past year, Medicus Pharma completed a business combination with affiliates in late 2024, enabling its public listing and access to capital markets; secured a strategic licensing agreement with Iconic Therapeutics for global rights to ICON-1001 in June 2025; raised approximately $10 million through warrant exercises and equity offerings to fund Phase 1 trials; and initiated first-in-human dosing for ICON-1001 in solid tumor patients, marking a key pipeline advancement. These developments underscore the company's accelerated growth in immuno-oncology and antimicrobial resistance segments, positioning it for multiple clinical readouts in 2026.